Loading
A phase 3 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by ArriVent BioPharma, Inc., active and no longer recruiting.
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) is a phase 3 interventional study registered as NCT05607550 by ArriVent BioPharma, Inc., with 398 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2025-08-15. Interventions recorded: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy. Conditions listed: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations. No results are recorded here; the registry entry is the source.
Shares ArriVent BioPharma, Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Furmonertinib, Small-cell lung cancer, Non-small-cell lung cancer.